Patients with chronic kidney disease (CKD) stages 3b or 4 experienced slower decline in estimated glomerular filtration rate 20 months after enrollment in a value-based kidney care program. Objectives ...
In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...
Eleanor Rivera receives funding from the National Institutes of Health. She is affiliated with the National Kidney Foundation and the Department of Veterans Affairs. For a disease afflicting 35.5 ...
Nine out of 10 people with chronic kidney disease only find out when it progresses to later stages. Here’s what we know about its risk factors—and why there's new reason to hope for more effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback